BETA SITE | REPORT ISSUES / GIVE FEEDBACK

Top Stories

U.S. Attorney’s office: Jails obligated to ensure access to opioid use medication

Renatta Signorini
By Renatta Signorini
2 Min Read Dec. 15, 2023 | 2 years Ago
Go Ad-Free today

The U.S. Attorney’s office in Philadelphia this week filed a statement of interest in federal court clarifying the obligation of state and local jails to ensure inmates have access to medication used to treat opioid use disorder.

The statement was filed less than two weeks after Allegheny County Jail health officials reached an agreement with the U.S. Department of Justice on a similar matter. Under the agreement, the county was to pay a person at the jail who was denied access to methadone $10,000 for violating the Americans with Disabilities Act.

Opioid use disorder is considered to be a disability covered by federal law.

The justice department’s statement was filed Monday in a civil matter related to similar issues in Delaware County.

U.S. Attorney Jacqueline C. Romero said, through the statement of interest, her office is reminding jails and prisons about their obligations as a way to fight the opioid epidemic.

“Every federal court to consider the question has found that jails likely violate the Americans with Disabilities Act when they refuse as a matter of policy to provide incarcerated persons access to opioid use disorder medication, regardless of the individual circumstances or medical needs,” the filing states.

In addition to the settlement with the Allegheny County Jail, federal authorities said they’ve reached similar agreements with jails and prisons in Eastern Kentucky and Massachusetts.

The Allegheny investigation was opened after the Department of Justice received a complaint that a man was denied methadone at the jail even though he had been receiving treatment from a licensed provider prior to his incarceration. Under the settlement, the county must contract with a licensed opioid treatment provider within six months and ensure all incarcerated people, within two months, are evaluated for opioid use disorder at admission and periodically afterward.

Share

Tags:

About the Writers

Renatta Signorini is a TribLive reporter covering breaking news, crime, courts and Jeannette. She has been working at the Trib since 2005. She can be reached at rsignorini@triblive.com.

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options